Core Viewpoint - Veracyte, Inc. is set to release its financial results for the fourth quarter and full year of 2025 on February 25, 2026, and anticipates significant revenue growth compared to the previous year [1]. Financial Results - For the fourth quarter of 2025, Veracyte expects total revenue to be between $138 million and $140 million, reflecting an increase of 16% to 18% compared to the same period in 2024 [1]. Upcoming Events - The company will host a conference call and webcast on February 25, 2026, at 4:30 p.m. Eastern Time to discuss the financial results and provide a business update [1]. - Veracyte will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, at 9:45 a.m. Pacific Time [1]. - The company is also scheduled to participate in the Wolfe Research Healthcare Conference and the Jefferies Global Healthcare Conference in November 2025 [1].

Core Viewpoint - Veracyte, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, at 9:45 a.m. Pacific Time [1] Group 1: Company Overview - Veracyte is a leading global diagnostics company focused on transforming cancer care for patients worldwide [3] - The company empowers clinicians with high-value insights to guide patients during critical moments in cancer diagnosis and treatment [3] - Veracyte's Diagnostics Platform offers high-performing cancer tests supported by extensive genomic and clinical data, advanced bioinformatics, AI capabilities, and a robust evidence-generation engine [3] Group 2: Presentation Details - Live audio webcasts of the company's presentations will be accessible on Veracyte's website [2] - A replay of the webcast will be available for 30 days after the live broadcast concludes [2]